Additionally, SUV39H2 knockdown significantly impaired cell viability in response to docetaxel treatment compared to control cells, indicating that SUV39H2 contributes to docetaxel resistance in prostate cancer (Sun et al., 2024). Here, SUV39H2 is linked to Familial prostate cancer.